About Moleculepath Bio
Founded in Boston in 2024 to make structure-guided hit discovery accessible to early-stage biotech teams that have the target but not the computational infrastructure.
A small, expert team closing the gap between pharma-grade computational chemistry and early-stage biotech.
The founding story.
Emilia Hartwell spent three years watching hit identification campaigns at early-stage biotechs cycle through the same failure pattern — large HTS runs against diversity libraries, hundreds of actives, weeks of counter-screening, then a hit list with no structural rationale for why any of them should work in a selectivity assay.
Every program had the structural data — crystal coordinates from a recent collaboration, binding site analyses from published homologs, FEP results from a consulting engagement that confirmed the binding hypothesis. But the connection between protein structure and library selection was made by intuition, not by systematic structural analysis. The fragment libraries were chosen from a catalog. The docking was run after the HTS, as a rationalization tool for hits that had already been identified. The structural constraint that should have shaped the campaign from the start was applied at the end.
The computational chemistry infrastructure to run structure-guided campaigns rigorously existed at large pharma. It was not accessible to a ten-person biotech with one medicinal chemist and six months to the next SAR review. Moleculepath Bio was founded to close that gap.
Mission
Make structure-guided small molecule discovery accessible to biotech discovery teams that have the target but not the computational infrastructure.
That is the exact statement. Not "empower biotech". Not "transform drug discovery". The mission is precise because the problem is precise: a specific class of early-stage biotech, with a specific type of structural asset, that lacks access to a specific kind of computational chemistry capability.
Structure before diversity
Start with the binding site, not the library. The pocket geometry constrains the answer before the screen begins.
Binding pose honesty
Deliver what the physics says, not what the client wants to hear. A high docking score with a physically unreasonable pose does not make the shortlist.
Partner-scale access
Early-stage biotechs deserve SBDD-quality hit matter. The engagement model exists to make this economically feasible for a team of five.
Explainability
Every hit comes with a reason it was selected. The structural rationale is a deliverable, not an optional annotation.
Scientific advisory board
Guided by domain experts across structural biology, medicinal chemistry, and computational methods.
Moleculepath's scientific advisory board brings expertise from across the drug discovery spectrum — academic structural biology, industrial medicinal chemistry, and computational free energy methods. The advisory board provides methodological guidance, protocol validation feedback, and scientific credibility for the platform's approach.
Emilia Hartwell
Founder
PhD in structural biology from MIT. Three years leading SBDD campaigns at Boston-area biotechs before founding Moleculepath Bio in 2024. Based at 101 Federal Street, Boston MA.
Company status
Seed stage, Boston, 2024.
Moleculepath Bio raised $3.5M seed in 2024 to build the structure-guided screening platform and partnership model. We are a team of four, operating from Boston's Financial District corridor, working with a select number of early-stage biotech discovery teams. Partner data is handled under mutual NDA, and structural data is treated as proprietary program information.
We are not a large CRO. We are a small team with deep structural biology and computational chemistry expertise — which is exactly what an early-stage biotech with a validated target and a short runway needs.
Have a target? Start with a conversation.
The founding story began with the observation that structural data was available but unused. Your program may be in exactly that position.
Discuss a Target